SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
AssigneeNovo Nordisk Healthcare AG
InventorUlla Hedner
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
Claims11
A method for treating a bleeding episode in a subject in need of such treatment, said method comprising administering intravenously to said subject a Factor VIIa equivalent, wherein said administering is in a single dose and said dose comprises a single-dose-effective amount of said Factor VIIa equivalent and wherein, subsequent to said administration, no further Factor VIIa equivalent is administered to said subject for a period of at least 4 hours.
A method for treating a bleeding episode, said method comprising administering to a subject in need of such treatment (i) a first amount of a Factor VIIa equivalent and (ii) a second amount of second coagulant agent, wherein said first and second amounts together comprise an aggregate effective amount for treating said bleeding and said aggregate effective amount is administered in a single dose.
Dependencies are inferred from the claim text.